#China #Hangzhou #J.P. Morgan #Hengdian Group #Apeloa Pharmaceutical

Hengdian Group Capital and Apeloa Pharmaceutical Attend J.P. Morgan Healthcare Conference 2025

Hengdian Group Capital (HgC) and its subsidiary Apeloa Pharmaceutical are gearing up for an important appearance at the 43rd Annual J.P. Morgan Healthcare Conference, taking place in San Francisco from January 13-16, 2025. This event is a significant gathering for key players in the healthcare industry, and both companies aim to bolster their connections and identify new opportunities.

Conference Overview

The J.P. Morgan Healthcare Conference is renowned for bringing together top executives, investors, and healthcare innovators to share insights and advancements in the field. With a roster of influential speakers and extensive networking opportunities, the conference serves as a vital platform for companies to showcase their innovations and explore collaborations.

Representatives from HgC, including CEO Gary Xu, and Apeloa's VP George Cai, will lead their teams in discussions aimed at fostering partnerships that can drive healthcare innovation forward. Their presence at this prestigious event signals their commitment to advancing global health solutions.

About Hengdian Group Capital

HgC is the investment arm of Hengdian Group, one of China’s largest privately-owned conglomerates, boasting over $350 million in assets under management. The company has positioned itself to invest in various sectors such as smart manufacturing, biotech, medtech, and consumer products, aligning its goals with the broader trend of globalization. HgC actively looks for synergetic acquisitions that can add value to its diverse portfolio. Recent notable investment activities include collaborations with Zelgen Pharmaceuticals and Corxel Pharmaceuticals, showcasing HgC's strategic approach to enhancing its market presence.

Apeloa Pharmaceutical's Contribution

Apeloa Pharmaceutical ranks among the top five Contract Development and Manufacturing Organizations (CDMOs) in China. With over 20 years in the sector, Apeloa has established a robust manufacturing footprint that includes eight production facilities and a workforce exceeding 2000 employees. Their research and development capabilities are extensive, covering advanced techniques such as flow chemistry and biocatalysis, enabling them to deliver high-quality pharmaceutical products to a global market. Apeloa has also received US FDA inspections 18 times since 2006, underscoring its compliance with international quality standards.

In 2024, Apeloa celebrated significant milestones, including:

• - Opening a new CDMO R&D Center in the Greater Boston area, dedicated to preclinical research and the development of advanced products.
• - Celebrating its 35th anniversary in Milan, reinforcing its commitment to future innovations in healthcare.
• - Receiving FDA approvals for critical medications like Amantadine Hydrochloride tablets and Metoprolol Succinate extended-release tablets, which are vital in managing conditions such as Parkinson's disease and hypertension.
• - Launching a sustainable production method for Gabapentin, aiming to reduce environmental impact while expanding its product offerings.

Conclusion

The participation of Hengdian Group Capital and Apeloa Pharmaceutical at the J.P. Morgan Healthcare Conference is an exciting development for the healthcare sector. Their commitment to fostering innovation and strategic partnerships highlights their role in the evolving world of healthcare. Following this event, the industry will likely see continued growth driven by the collaborative efforts of these influential companies.

To arrange meetings or discussions during the conference, interested parties can reach out to HgC at info@hgcapital.com or Apeloa at contact@apeloa.com.

This engagement represents not just an opportunity for development but a concerted effort to redefine the future of healthcare through technological and scientific advancements.